Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA

Claudia Bianco; G Meini; Barbara Rossetti; S Lamonica; Annalisa Mondi; S Belmonti; L Fanti; Nicoletta Ciccarelli; Simona Di Giambenedetto; M Zazzi; Andrea De Luca

doi:10.7448/IAS.17.4.19791

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA

Claudia Bianco
, G Meini
, Barbara Rossetti
, S Lamonica
, Annalisa Mondi
, S Belmonti
, L Fanti
, Nicoletta Ciccarelli
, Simona Di Giambenedetto
, M Zazzi
, Andrea De Luca

Risultato della ricerca: Contributo in rivista › Articolo di conferenza › peer review

Abstract

Raltegravir intensification is associated with an increase in 2-LTR episomal HIV DNA= circles, indicating a persistent low-level replication, in some individuals in ART with suppressed HIV RNA. We aimed at monitoring residual plasma HIV RNA and cellular HIV DNA in virologically suppressed patients switching to a raltegravir-based regimen.

Lingua originale	Inglese
pagine (da-a)	19791-19791
Numero di pagine	1
Rivista	Journal of the International AIDS Society
Volume	17
DOI	https://doi.org/10.7448/IAS.17.4.19791
Stato di pubblicazione	Pubblicato - 2014
Evento	HIV Drug Therapy Glasgow Congress 2014 - Glasgow Durata: 23 ott 2014 → 26 ott 2014

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

DNA
HIV
therapy

Accesso al documento

10.7448/IAS.17.4.19791

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{f20ce332afe04d7da08ec37fe71185f9,

title = "Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA",

abstract = "Raltegravir intensification is associated with an increase in 2-LTR episomal HIV DNA= circles, indicating a persistent low-level replication, in some individuals in ART with suppressed HIV RNA. We aimed at monitoring residual plasma HIV RNA and cellular HIV DNA in virologically suppressed patients switching to a raltegravir-based regimen.",

keywords = "DNA, HIV, therapy, DNA, HIV, therapy",

author = "Claudia Bianco and G Meini and Barbara Rossetti and S Lamonica and Annalisa Mondi and S Belmonti and L Fanti and Nicoletta Ciccarelli and \{Di Giambenedetto\}, Simona and M Zazzi and \{De Luca\}, Andrea",

year = "2014",

doi = "10.7448/IAS.17.4.19791",

language = "English",

volume = "17",

pages = "19791--19791",

journal = "Journal of the International AIDS Society",

issn = "1758-2652",

publisher = "John Wiley \& Sons Inc.",

note = "HIV Drug Therapy Glasgow Congress 2014 ; Conference date: 23-10-2014 Through 26-10-2014",

}

TY - JOUR

T1 - Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA

AU - Bianco, Claudia

AU - Meini, G

AU - Rossetti, Barbara

AU - Lamonica, S

AU - Mondi, Annalisa

AU - Belmonti, S

AU - Fanti, L

AU - Ciccarelli, Nicoletta

AU - Di Giambenedetto, Simona

AU - Zazzi, M

AU - De Luca, Andrea

PY - 2014

Y1 - 2014

N2 - Raltegravir intensification is associated with an increase in 2-LTR episomal HIV DNA= circles, indicating a persistent low-level replication, in some individuals in ART with suppressed HIV RNA. We aimed at monitoring residual plasma HIV RNA and cellular HIV DNA in virologically suppressed patients switching to a raltegravir-based regimen.

AB - Raltegravir intensification is associated with an increase in 2-LTR episomal HIV DNA= circles, indicating a persistent low-level replication, in some individuals in ART with suppressed HIV RNA. We aimed at monitoring residual plasma HIV RNA and cellular HIV DNA in virologically suppressed patients switching to a raltegravir-based regimen.

KW - DNA

KW - HIV

KW - therapy

KW - DNA

KW - HIV

KW - therapy

UR - http://hdl.handle.net/10807/61290

U2 - 10.7448/IAS.17.4.19791

DO - 10.7448/IAS.17.4.19791

M3 - Conference article

SN - 1758-2652

VL - 17

SP - 19791

EP - 19791

JO - Journal of the International AIDS Society

JF - Journal of the International AIDS Society

T2 - HIV Drug Therapy Glasgow Congress 2014

Y2 - 23 October 2014 through 26 October 2014

ER -

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA

Abstract

OSS delle Nazioni Unite

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo